Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle
Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt
Subscribe To Our Newsletter & Stay Updated